# US 2016/0207920 A1 · Isoergoline compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0207920 A1
- Document ID: US20160207920A1
- Status: Published application
- Kind: A1
- Application number: 15/001,246
- Filed: 2016-01-20
- Published: 2016-07-21
- Earliest claimed: 2015-01-20
- Assignees: Xoc Pharmaceuticals, Inc.
- Applicants: Xoc Pharmaceuticals, Inc.
- Inventors: THOMAS ARMER; GEOFF MCKINLEY; SCOTT BORLAND; MIGUEL GUZMAN
- Web page: https://patentgrep.com/patent/US20160207920A1

## CPC

- C07D 457/12: Nitrogen atoms
- A61P 25/06: Antimigraine agents
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 471/06: Peri-condensed systems
- C07D 495/06: Peri-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are isoergoline compounds and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1A, 5-HT1B and 5-HT1D receptors without agonizing the 5-HT2B receptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B adrenergic alpha2A and/or the alpha2B receptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

## Claims

### Claim 1

A compound of structural Formula (I):
or polymorphs, salts, hydrates or solvates thereof, wherein:
R1 is hydrogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, halo, haloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, —S(O)jR101, —C(O)NR102R103 or —CO2R104;
R2 is alkyl, substituted alkyl, acyl, substituted acyl, halo, haloalkyl, heteroalkyl, substituted heteroalkyl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, —NO2, —N3, —S(O)kR110, —OR111, —NR112R113, —C(O)NR114R115, —OC(O)NR116R117, —CO2R118 or —OC(O)R119;
n is 0, 1, 2 or 3;
R3 is hydrogen, alkyl, substituted alkyl, haloalkyl, heteroalkyl, substituted heteroalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;
R4 and R5 are independently hydrogen, alkyl, substituted alkyl, halo, haloalkyl, —OR120, —OC(O)NR121R122, —OC(O)R123 or together with the atoms to which they are attached form a double bond;
R6 and R7 are independently hydrogen, acyl, subsisted acyl, alkyl, substituted alkyl, haloalkyl, heteroalkyl or substituted heteroalkyl, provided that both R6 and R7 are not both hydrogen or alkyl or combinations thereof;
X is —S—, —SO2— or —NR8—;
a is 0 or 1;
R8, R102-R104 and R111-R123 are independently hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, haloalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;
R101 and R110 are independently alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, halo, haloalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl; and
optionally, R1 and R8 along with the atoms to which they are attached form a 5, 6 or 7 membered ring;
provided that R1 and R8 are not both hydrogen;
provided that R1 and R8 are not both alkyl;
provided that R1 and R8 are not both substituted alkyl;
provided that R1 is not hydrogen when R8 is alkyl or substituted alkyl; and
provided that R8 is not hydrogen when R1 is alkyl or substituted alkyl.

### Claim 2 (depends on 1)

The compound of claim 1 of structural formula (II)
wherein R7 is
R10 is alkyl, substituted alkyl, haloalkyl, heteroalkyl, or substituted heteroalkyl;
Y is —S(O)lR11, —OR12 or —NR13R14;
l is 0, 1 or 2;
b is 1, 2, 3 or 4;
R11 is alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, halo, haloalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl; and
R12-R14 are independently hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, haloalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl.

### Claim 3 (depends on 2)

The compound of claim 2, wherein:
R1 is hydrogen, alkyl, substituted alkyl, heteroalkyl or substituted heteroalkyl;
R2 is alkyl, substituted alkyl, acyl, halo, —OR111, —C(O)NR114R115 or —CO2R118;
n is 0 or 1;
R3 is hydrogen, alkyl, substituted alkyl, heteroalkyl or substituted heteroalkyl;
R4 and R5 are independently hydrogen, alkyl, substituted alkyl, —OR120 or together with the atoms to which they are attached form a double bond;
R10 is alkyl or substituted alkyl;
b is 1 or 2;
Y is —OR12 or —NR13R14,
R8, R12-R14, R102-R104 and R111-R123 are independently hydrogen, alkyl, substituted alkyl, arylalkyl or substituted arylalkyl; and
R11, R101 and R110 are independently alkyl, substituted alkyl, arylalkyl or substituted arylalkyl.

### Claim 4 (depends on 2)

The compound of claim 2, wherein:
R1 is hydrogen, alkyl, substituted alkyl, heteroalkyl or substituted heteroalkyl;
R2 is alkyl, substituted alkyl, acyl, halo, —OR111, —C(O)NR114R115 or —CO2R118;
n is 0 or 1;
R3 is hydrogen, alkyl, substituted alkyl, heteroalkyl or substituted heteroalkyl;
R4 and R5 are independently hydrogen, alkyl, substituted alkyl, —OR120 or together with the atoms to which they are attached form a double bond;
R10 is alkyl or substituted alkyl;
b is 1 or 2;
Y is —OR12 or —NR13R14,
R8, R12-R14, R102-R104 and R111-R123 are independently hydrogen, alkyl or arylalkyl; and
R11, R101 and R110 are independently alkyl or arylalkyl.

### Claim 5 (depends on 2)

The compound of claim 2, wherein:
R1 is hydrogen, alkyl, substituted alkyl, heteroalkyl or substituted heteroalkyl;
R2 is alkyl, substituted alkyl, acyl, halo, —OR111, —C(O)NR114R115 or —CO2R118;
n is 0 or 1;
R3 is hydrogen, alkyl, substituted alkyl, heteroalkyl or substituted heteroalkyl;
R4 and R5 are independently hydrogen, alkyl, substituted alkyl, —OR120 or together with the atoms to which they are attached form a double bond;
R10 is alkyl or substituted alkyl;
b is 1 or 2;
Y is —OR12 or —NR13R14,
R8, R12-R14, R102-R104 and R111-R123 are hydrogen, alkyl or arylalkyl; and
R11, R101 and R110 are independently alkyl or arylalkyl.

### Claim 6 (depends on 2)

The compound of claim 2, wherein:
R1 is hydrogen, alkyl or substituted alkyl;
R2 is alkyl, substituted alkyl, acyl, halo, —OR111, —C(O)NR114R115 or —CO2R118;
R3 is hydrogen, alkyl or alkyl substituted with one or more fluorine atoms;
R4 and R5 are independently hydrogen, —OR120 or together with the atoms to which they are attached form a double bond;
R10 is alkyl or alkyl substituted with one or more fluorine atoms;
b is 1;
Y is —OR12 or —NR13R14,
R8, R12-R14, R102-R104 and R111-R123 are independently hydrogen, alkyl, substituted alkyl, arylalkyl or substituted arylalkyl; and
R11, R101 and R110 are independently alkyl, substituted alkyl, arylalkyl or substituted arylalkyl.

### Claim 7 (depends on 2)

The compound of claim 2, wherein:
R1 is hydrogen, alkyl or substituted alkyl;
R2 is alkyl, substituted alkyl, acyl, halo, —OR111, —C(O)NR114R115 or —CO2R118; R3 is hydrogen or alkyl;
R4 and R5 are independently hydrogen, —OR120 or together with the atoms to which they are attached form a double bond;
R6 is hydrogen;
R7 is alkyl or alkyl substituted with fluorine;
b is 1;
Y is —OR12 or —NR13R14,
R8, R12-R14, R102-R104 and R111-R123 are independently hydrogen, alkyl, substituted alkyl, arylalkyl or substituted arylalkyl; and
R11, R101 and R110 are independently alkyl, substituted alkyl, arylalkyl or substituted arylalkyl.

### Claim 8 (depends on 2)

The compound of claim 2, wherein:
R1 is hydrogen, alkyl or substituted alkyl;
R2 is alkyl, substituted alkyl, acyl, halo, —OR111, —C(O)NR114R115 or —CO2R118;
R3 is hydrogen or alkyl;
R4 and R5 are independently hydrogen, —OR120 or together with the atoms to which they are attached form a double bond;
R10 is alkyl or alkyl substituted with one or more fluorine atoms;
b is 1;
Z is —OR13,
R8, R13, R102-R104 and R111-R123 are hydrogen, alkyl or arylalkyl; and
R11, R101 and R110 are independently alkyl or arylalkyl.

### Claim 9 (depends on 2)

The compound of claim 2, wherein:
R1 is halo, hydrogen, alkyl or substituted alkyl;
R3 is alkyl or alkyl substituted with one or more fluorine atoms;
R10 is alkyl or substituted alkyl; and
Y is —OR12.

### Claim 10 (depends on 2)

The compound of claim 2 of structural formula (III):
wherein R7 is
and
R10 is methyl, b is 1 and Y is OH.

### Claim 11 (depends on 2)

The compound of claim 2 of structural Formula (IV):
wherein:
R1 is halo, hydrogen, alkyl or substituted alkyl;
R3 is alkyl;
R7 is;
R10 is alkyl or substituted alkyl; and
Y is —OR12.

### Claim 12 (depends on 11)

The compound of claim 11 of structural Formula (V):
wherein R7 is
and
R10 is methyl, b is 1 and Y is OH.

### Claim 13 (depends on 11)

The compound of claim 11 of structural Formula (VI):
wherein R7 is
and
R10 is methyl, b is 1 and Y is OH.

### Claim 14 (depends on 1)

A composition comprising the compound of claim 1 and a vehicle.

### Claim 15 (depends on 1)

A method of treating and/or preventing migraine, ALS, Alzheimer's disease, Parkinson's disease, extra-pyramidal disorders, depression, nausea, emesis, restless legs syndrome, insomnia, aggression, Huntington's disease, cardiopulmonary, fibrogenesis, pulmonary arterial hypertension, anxiety, drug addictions, dystonia, parasomnia or hyperprolactinemia in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound claim 1.

### Claim 16 (depends on 1)

A method of agonizing the D2 receptor in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 17 (depends on 1)

A method of antagonizing the D3 receptor in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 18 (depends on 1)

A method of agonizing the 5-HT1D receptor in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 19 (depends on 1)

A method of agonizing the 5-HT1A receptor in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 20 (depends on 1)

A method of selectively agonizing the 5-HT1D receptor over the 5-HT1B receptor in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 21 (depends on 1)

A method of selectively agonizing the 5-HT2C receptor over the 5-HT2A or 5-HT2B receptor in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 22 (depends on 1)

A method of agonizing the 5-HT2C receptor in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 23 (depends on 1)

A method of providing functional antagonist activity at the 5-HT2B receptor or 5-HT7 receptor or both in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 24 (depends on 1)

A method of providing functional antagonist activity at the adrenergic receptors in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.
